Gillian McGovern, Editor

Study authors suggest that VA and health care professionals should educate patients on the medical evidence, gaps, policies, and laws related to cannabis.

With this action, dupilumab has become the first and only FDA-approved treatment for allergic fungal rhinosinusitis.

The authors urge air quality interventions to promote and support dementia prevention strategies.

A pressure vibration device can cut propofol injection pain in patients undergoing surgeries, matching low-dose ketamine without extra adverse events.

The biosimilar is a cost-effective treatment for patients with conditions caused by cancer treatment.

Universal aspirin at the first prenatal visit lowers severe preeclampsia rates in high-risk pregnancies, delaying onset without raising hemorrhage or placental abruption risk.

ALZ-801, an oral anti–amyloid oligomer therapy, shows cognitive, functional, and brain-volume benefits in the mild cognitive impairment (MCI) stage of Alzheimer disease, with supportive biomarkers and no edema risk.

Both formulations were also well-tolerated and withdrawal was rare.

The label change removes boxed warnings of cardiovascular disease, breast cancer, and probable dementia from certain hormone replacement therapy products.

The Break Up Big Medicine Act aims to address structural conflicts of interest.

The updates allow for patients of reproductive age to complete pregnancy tests at home during or after treatment.

The most pronounced association was observed when individuals consumed 2 to 3 cups of caffeinated coffee per day.

Intranasal ketamine may remain a potentially viable treatment method for acute pain.

The HHS secretary overstated preliminary research showing the benefits of a keto diet in patients with schizophrenia who remain adherent to medications.

In addition to increased prevalence, the age of diagnosis has also decreased.

Study results suggest young participants who survived cancer have difficulty in areas such as memory, attention, and ability to process information compared with those who did not have cancer.

The FDA cited human factors unrelated to the drug's efficacy as the reason for rejection.

The authors suggested that future research investigate emerging blood-based biomarkers and explore temporal associations between sleep duration and Alzheimer disease biomarker changes.

The FDA prioritizes centanafadine's review for ADHD treatment, offering a novel, once-daily oral option for diverse patient needs.

CMS announces the selection of 15 high-cost drugs for Medicare price negotiations, aiming to reduce prescription costs for older adults and taxpayers.

Recent research reveals no link between menopause hormone therapy and dementia risk, urging further studies to clarify its effects on cognitive health.

The study found that anxiety and depression in those with Parkinson disease were significantly associated with fatigue severity.

Recent research links depression to increased risk of Lewy body dementia and Parkinson disease, emphasizing the need for early detection and awareness.

A study determined that lifestyle factors and comorbidities were more likely to be associated with the onset of diabetes.

Pharmacists enhance health care delivery by managing medication refills, addressing drug shortages, and supporting chronic disease management.

Recent research reveals no significant link between prenatal acetaminophen use and increased risks of autism or ADHD in children, challenging FDA claims.

Preeclampsia significantly raises the risk of chronic kidney disease (CKD) later in life, highlighting the need for targeted postpartum monitoring for affected women.

According to the news release, the manufacturers have 30 days to respond.

AbbVie partners with the Trump administration to enhance drug affordability and access, committing to significant investments in US pharmaceutical innovation.

The treatment was granted a Prescription Drug User Fee Act target action date of May 10, 2026.